TEAS Plus New Application

PTO- 1478

Approved for use through 10/31/2024. OMB 0651-0009

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

---

PTO- 1478

Approved for use through 10/31/2024. OMB 0651-0009

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Trademark/Service Mark Application, Principal Register

TEAS Plus Application

Serial Number: 97864443

Filing Date: 03/30/2023

To the Commissioner for Trademarks:

MARK: FYDINMI (Standard Characters, see mark)
The literal element of the mark consists of FYDINMI. The mark consists of standard characters, without claim to any particular font style, size, or color.
The applicant, Glaxo Group Limited, a private company limited by shares (prc) legally organized under the laws of United Kingdom, having an address of
      980 Great West Road
      Brentford, Middlesex TW89GS
      England
      XXXX

requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:

For specific filing basis information for each item, you must view the display within the Input Table.
International Class 005:  Vaccines; Anti-infectives; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders

Priority based on foreign filing: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services and asserts a claim of priority based on United Kingdom application number UK00003860018, filed 12/16/2022.
INTENT TO PERFECT 44(d) : At this time, the applicant intends to rely on Section 44(e) as a basis for registration. If ultimately the applicant does not rely on Section 44(e) as a basis for registration, a valid claim of priority may be retained.

Based on Foreign Registration: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services, and submits a copy of United Kingdom registration number UK00003860018, and/or proof of renewal, registered 12/16/2022 with a renewal date of __________ and an expiration date of 12/16/2032, and translation thereof, if appropriate.

Original PDF file:
reg-15251561-104641476_._ FYDINMI_UK_REG_CERT.pdf
Converted PDF file(s) (2 pages)
Foreign Registration-1
Foreign Registration-2

The foreign registration that is the basis of the U.S. application under §44(e) of the Trademark Act includes a claim of standard characters or the country of origin's standard character equivalent.



The owner's/holder's proposed attorney information: Elizabeth K. Rucki. Other appointed attorneys are Christopher M. Hanes. Elizabeth K. Rucki of GSK, is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX, and the attorney(s) is located at
      Legal Brand Protection
      410 Blackwell Street
      Durham, North Carolina 27701
      United States
      919-353-8081(phone)
      trademarks@gsk.com
The docket/reference number is 84227582.
Elizabeth K. Rucki submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.

The applicant's current Correspondence Information:

Elizabeth K. Rucki

PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@gsk.com        SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).

A fee payment in the amount of $250 has been submitted with the application, representing payment for 1 class(es).

Declaration

	Basis: If the applicant is filing the application based on use in commerce under 15 U.S.C. § 1051(a): The signatory believes that the applicant is the owner of the trademark/service mark sought to be registered; The mark is in use in commerce and was in use in commerce as of the filing date of the application on or in connection with the goods/services in the application; The specimen(s) shows the mark as used on or in connection with the goods/services in the application and was used on or in connection with the goods/services in the application as of the application filing date; and To the best of the signatory's knowledge and belief, the facts recited in the application are accurate. And/Or If the applicant is filing the application based on an intent to use the mark in commerce under 15 U.S.C. § 1051(b), § 1126(d), and/or § 1126(e): The signatory believes that the applicant is entitled to use the mark in commerce; The applicant has a bona fide intention to use the mark in commerce and had a bona fide intention to use the mark in commerce as of the application filing date on or in connection with the goods/services in the application; and To the best of the signatory's knowledge and belief, the facts recited in the application are accurate.
	To the best of the signatory's knowledge and belief, no other persons, except, if applicable, concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services of such other persons, to cause confusion or mistake, or to deceive.
	To the best of the signatory's knowledge, information, and belief, formed after an inquiry reasonable under the circumstances, the allegations and other factual contentions made above have evidentiary support.
	The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any registration resulting therefrom, declares that all statements made of his/her own knowledge are true and all statements made on information and belief are believed to be true.

Declaration Signature

Signature: /Elizabeth K. Rucki/   Date: 03/30/2023
Signatory's Name: Elizabeth K. Rucki
Signatory's Position: Attorney of record, Texas Bar member
Signatory's Phone Number: 919-353-8081
Signature method: Sent to third party for signature
Payment Sale Number: 97864443
Payment Accounting Date: 03/30/2023

Serial Number: 97864443
Internet Transmission Date: Thu Mar 30 11:52:04 ET 2023
TEAS Stamp: USPTO/FTK-XXX.XX.XX.X-202303301152050882
39-97864443-8601d503fb670d14191dbfd43394
553ed18a44a3e9a62f7ccfb31d5292bb3c7d-DA-
52049175-20230330104641476237